IP Library Granted Patent US 8,829,005
Granted Patent B2
US 8,829,005 · App. 13/899,321 · Granted Sep 9, 2014

Ophthalmic formulations of cetirizine and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,829,005
App. No.
13/899,321
Granted
Sep 9, 2014
Kind
B2
Abstract

The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.

Claims (11)

1. A method for alleviating a sign or symptom of allergic conjunctivitis by topically administering to an eye of a subject in need thereof an ophthalmic formulation comprising a single active ingredient consisting of 0.24% (w/v) cetirizine twice daily, wherein the ophthalmic formulation

a) does not contain a cyclodextrin;

b) comprises 1% Polyethylene Glycol 400, NF, 0.2% Dibasic Sodium Phosphate, Anhydrous, USP, 0.25% Hypromellose, USP, 0.1% Polysorbate 80, NF, 1.8% Glycerin, USP, 0.01% Benzalkonium Chloride, NF, and Purified Water, USP; and

c) has a pH 6.8-7.2.

2. The method of claim 1 , wherein ophthalmic formulation is an aqueous formulation, an ointment, an oil, a suspension, an emulsion, or incorporated in a drug delivery device.

3. The method of claim 1 , wherein the sign or symptom is itching.

4. The method of claim 1 , wherein said subject has ocular itching, ocular redness and lid swelling.

5. The method of claim 1 , wherein said subject has severe ocular itching, severe ocular redness or severe lid swelling.

6. The method of claim 1 , wherein said composition is comfortable upon instillation.

7. The method of claim 1 , wherein the sign or symptom is a nasal sign or symptom.

8. The method of claim 7 , wherein the nasal sign or symptom is nasal congestion, nasal itching, ear itching, palate itching, or runny nose (rhinorrhea).

Assignments (4)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Oct 9, 2020
From: HAYFIN SERVICES LLP
To: EYEVANCE PHARMACEUTICALS LLC
Reel/Frame 054172/0632 →
SECURITY INTEREST Recorded Oct 17, 2019
From: EYEVANCE PHARMACEUTICALS LLC, AS GRANTOR
To: HAYFIN SERVICES LLP, AS COLLATERAL AGENT
Reel/Frame 050751/0051 →
CHANGE OF NAME Recorded Mar 4, 2016
From: ACIEX THERAPEUTICS, INC.
To: NICOX OPHTHALMICS, INC.
Reel/Frame 038007/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2013
From: ABELSON, MARK BARRY; CHAPIN, MATTHEW JONATHAN; GOMES, PAUL; MINNO, GEORGE; NICE, JACKIE
To: ACIEX THERAPEUTICS, INC.
Reel/Frame 030468/0343 →